NPS Pharmaceuticals Completes Patient Randomization In Phase 3 REPLACE Study Of NPSP558 In Hypoparathyroidism
Links shared publicly online about this topic.
- 466total visits
NPS Pharmaceuticals Completes Patient Randomization In Phase 3 REPLACE Study Of NPSP558 In Hypoparathyroidism
NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, have announced the randomization o
View full resource at medicalnewstoday.com
Tags: Endocrinology, Parathyroid Disorder, Disease and Condition, Pharma
Most Recently Shared on March 12, 2011 at 4:05 pm By:
NPS Pharmaceuticals Completes Patient Randomization In Phase 3 REPLACE Study Of NPSP558 In Hypoparathyroidism: N... http://bit.ly/fowA4g
NPS Pharmaceuticals Completes Patient Randomization In Phase 3 REPLACE Study Of NPSP558 In Hypoparathyroidism
medicalnewstoday.com — “NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, have announced the randomization o” View full resource at medicalnewstoday.com
Most Recently Shared on March 3, 2011 at 10:05 am By:
NPS Pharmaceuticals Completes Patient Randomization In Phase 3 REPLACE Study Of NPSP558 In Hypoparathyroidism http://mnt.to/3RNy
Advertisement
